Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Issue of Share Options

10 Nov 2014 07:00

RNS Number : 5245W
Angle PLC
10 November 2014
 



For immediate release

10 November 2014

 

ANGLE plc

("ANGLE" or the "Company")

 

ISSUE OF SHARE OPTIONS

 

ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that, as described in the Remuneration Report of the Company's 2014 Annual Report, it has finalised share option arrangements to take the place of the Proceeds of Realised Investments Bonus Plan ("the PORI").

 

The PORI, which has been in operation since 1 May 2010, allocated 10% of all cash realisations to a bonus pool for executive directors and staff. The Company has changed significantly since 2010 and is now a specialist medtech operating company. Consequently the Remuneration Committee determined that the PORI is no longer appropriate and has decided to replace it with a standard share option scheme.

 

In relation to closure of the PORI, the Remuneration Committee has approved the issue of 1,500,000 share options to the Company's executive directors. The Remuneration Committee has also approved the issue of 1,000,000 share options to certain new and existing staff. Following the issue of the new share options, the Company will have outstanding options over a total of 6,906,000 ordinary shares being 12.8% of the issued and to be issued share capital. This leaves c. 1,700,000 options unallocated within the approved limit of up to 16% of the issued and to be issued share capital from time to time.

 

The exercise price for the new share options is set at the current mid market price of 86.25 pence per share and the options are subject to service and/or performance conditions.

 

The new share options granted to the executive directors have a term of ten years and are, subject to a performance condition that the target share price has been attained, exercisable after five years or on the sale of Parsortix, whichever is the earlier event. Each quarter of the allocation will have a target share price of £2.00, £2.25, £2.50 and £2.75 respectively. The Remuneration Committee will, from time to time, consider the issue of further share options as long as they remain within the 16% option pool limit. To the extent these are issued to the executive directors, they will be subject to the performance condition that the share price has risen by at least 50% from the share price when the option is issued.

 

Following the issue of the new share options, the total number of share options held by the executive directors of the Company will be:

 

Options Before issue After issue Increase

Andrew Newland, Chief Executive 1,950,000 2,950,000 1,000,000

Ian Griffiths, Finance Director 1,000,000 1,500,000 500,000

 

The non-executive directors do not hold share options.

 

 

ANGLE Chairman, Garth Selvey, commented:

"The new remuneration structure reflects the changed circumstances of the business and is now conventional for a business of this type providing very real incentives for the executive and management team. At the same time, bonus amounts and option numbers are capped and provision also exists for executive bonus payments to be discharged in the form of share options within those limits. This ensures that the Company is focused on achieving its goals and investors, both existing and new, have clear information on which to base their decision processes."

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Dr Christopher Golden (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles

020 7466 5000

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUBOBRSAAARAA
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.